Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood‐derived immune cell viability

Small molecule inhibitors selectively targeting the immunoproteasome subunit β5i are currently being developed for the treatment of autoimmune disorders. However, patients carrying loss‐of‐function mutations in the gene encoding β5i (Psmb8) suffer from the proteasome‐associated autoinflammatory synd...

Descripción completa

Detalles Bibliográficos
Autores principales: Pletinckx, Katrien, Vaßen, Silke, Schlusche, Ilka, Nordhoff, Sonja, Bahrenberg, Gregor, Dunkern, Torsten R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581949/
https://www.ncbi.nlm.nih.gov/pubmed/31236277
http://dx.doi.org/10.1002/prp2.482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581949/
https://www.ncbi.nlm.nih.gov/pubmed/31236277
http://dx.doi.org/10.1002/prp2.482

Ejemplares similares